Investors

Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

Stock Quote

Price

Change

High

View Details Stock Lookup

Date	Title and Summary
Toggle Summary 18 Oct '19	Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community - New open-label extension data from the Phase 2 OASIS trial for etrasimod in ulcerative colitis - Arena sponsored breakfast symposium: Will oral therapies change the IBD treatment landscape? - Visit Arena in the exhibit hall at booth #78 SAN DIEGO , Oct. General
Toggle Summary 26 Sep '19	Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting SAN DIEGO, Calif. , Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of General

Date

Title and Summary

Oct '19

Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community

- New open-label extension data from the Phase 2 OASIS trial for etrasimod in ulcerative colitis - Arena sponsored breakfast symposium: Will oral therapies change the IBD treatment landscape? - Visit Arena in the exhibit hall at booth #78 SAN DIEGO , Oct.

General

Sep '19

Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

SAN DIEGO, Calif. , Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, in development for a range of

General